Infantile hepatic hemangiomas: looking backwards and forwards

Area of Science:

• Pediatric Gastroenterology and Hepatology
• Vascular Anomalies
• Oncology

Background:

• Infantile hepatic hemangiomas (IHHs) are common benign liver tumors in infants.
• Their classification and pathogenesis remain unclear, presenting diagnostic and therapeutic challenges.
• While often asymptomatic, severe IHH can cause life-threatening complications.

Purpose of the Study:

• To provide a comprehensive overview of infantile hepatic hemangiomas.
• To summarize current knowledge on IHH epidemiology, pathogenesis, clinical features, and diagnosis.
• To review emerging treatment strategies, particularly oral propranolol, and discuss future perspectives.

Main Methods:

• Literature review and synthesis of existing research on IHH.
• Analysis of epidemiological data, pathogenic mechanisms, and clinical presentations.
• Evaluation of diagnostic approaches and therapeutic interventions, including propranolol.

Main Results:

• IHHs share proliferative and involutional phases with cutaneous hemangiomas but lack clear definitions.
• Clinical manifestations are diverse, ranging from asymptomatic to severe complications like cardiac failure.
• Oral propranolol demonstrates efficacy in tumor remission and symptom regression for IHH.

Conclusions:

• Standardized definitions and a deeper understanding of IHH pathogenesis are crucial.
• Early diagnosis and management are vital due to potential severe complications.
• Oral propranolol represents a promising systemic treatment, yet optimal strategies for severe cases require further investigation.